Pancreatic ductal adenocarcinoma (PDA) is characterized by an immune-suppressive tumor
microenvironment that renders it largely refractory to immunotherapy. We implemented a …

Here, we describe an unexpected cross-talk between Tregs and fibroblasts in pancreatic
cancer. Treg depletion resulted in differentiation of inflammatory fibroblast subsets, in turn …

Pancreatic ductal adenocarcinoma (PDA) is accompanied by reprogramming of the local
microenvironment, but changes at distal sites are poorly understood. We implanted biomaterial …

Background & Aims Oncogenic Kirsten Rat Sarcoma virus (KRAS) is the hallmark mutation
of human pancreatic cancer and a driver of tumorigenesis in genetically engineered mouse …

Oncogenic mutations in BRAF are believed to initiate serrated colorectal cancers; however,
the mechanisms of BRAF-driven colon cancer are unclear. We find that oncogenic BRAF …

Abstract Characterization of ALDH + DIPGs coupled with targeting MAPK/PI3K/mTOR
signaling provides an impetus for molecularly targeted therapy aimed at addressing the CSC …

Pancreatic Ductal Adenocarcinoma (PDA) has an exceedingly poor prognosis with only 10%
5-year survival rate. Kras mutations are found in over 90% of cases of pancreatic cancer …

… Sirihorachai … Garcia, Veerin R. Sirihorachai, Elizabeth R. Lawlor. Emergence of
persister cells following bromodomain inhibition in Ewing sarcoma [abstract]. …

A key feature of pancreatic cancer is the extensive fibroinflammatory stroma that constitutes
the bulk of the tumor volume. The stroma includes fibroblasts, extracellular matrix, and …

Pancreatic ductal adenocarcinoma (PDA) is the third leading cause of cancer related death,
with a five-year survival rate of 11%. Not only is PDA often diagnosed at advanced stages, …